Concepedia

Metformin Tolerability

Metformin Tolerability is a clinical pharmacological construct that denotes the degree to which a patient can adhere to metformin therapy without experiencing unacceptable gastrointestinal or systemic adverse effects.

374

Publications

32.9K

Citations

2.2K

Authors

953

Institutions

Publications per year

2017–2026

108

Parents

Publications

374

Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus

Silvio E. Inzucchi, David Maggs, Geralyn Spollett et al. · New England Journal of Medicine · 1998 · 799 citations · Full text

, , +16

Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes

Robert J. Heine, Luc F. Van Gaal, Don Johns et al. · Annals of Internal Medicine · 2005 · 797 citations

, , +17

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone

B Charbonnel, Avraham Karasik, Ji Liu et al. · Diabetes Care · 2006 · 790 citations · Full text

, , +17

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

William T. Cefalu, Lawrence A. Leiter, Kun‐Ho Yoon et al. · The Lancet · 2013 · 724 citations

, , +15

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

Michael A. Nauck, Gary Meininger, Lisa Terranella et al. · Diabetes Obesity and Metabolism · 2007 · 667 citations · Full text

, , +17

1–5 of 374

Authors

2.2K

  1. JR
    Julio Rosenstock

    Dallas Diabetes Research Center, United States

    21 publications · 3.8K citations

    20

    h-index

  2. SS
    Samuel S. Engel

    Merck & Co., Inc., Rahway, NJ, USA (United States), United States

    14 publications · 1.3K citations

    13

    h-index

  3. JP
    Juan P. Frías

    National Research Institute, United States

    10 publications · 990 citations

    10

    h-index

  4. KD
    Keith D. Kaufman

    Merck & Co., Inc., Rahway, NJ, USA (United States), United States

    10 publications · 845 citations

    10

    h-index

  5. MA
    Michael A. Nauck

    Diabeteszentrum Bad Lauterberg, Germany

    9 publications · 2.2K citations

    9

    h-index

1–5 of 2.2K

Institutions

953

  1. Dallas Diabetes Research Center

    Dallas, United States

    22 h-index

    23 publications

    4K citations

  2. Merck & Co., Inc., Rahway, NJ, USA (United States)

    Rahway, United States

    19 h-index

    141 publications

    19K citations

  3. Bristol-Myers Squibb (United States)

    New York, United States

    17 h-index

    45 publications

    3.4K citations

  4. Boehringer Ingelheim (Germany)

    Ingelheim, Germany

    16 h-index

    58 publications

    12.7K citations

  5. AstraZeneca (Sweden)

    Södertälje, Sweden

    13 h-index

    17 publications

    1.2K citations

  6. AstraZeneca (United States)

    Wilmington, United States

    13 h-index

    25 publications

    2K citations

  7. Pfizer (United States)

    New York, United States

    13 h-index

    42 publications

    3.3K citations

  8. University of Pisa

    Pisa, Italy

    12 h-index

    13 publications

    2.1K citations

1–8 of 953

Venues

  1. Diabetes Obesity and Metabolism

    64 publications · 7.2K citations

    42

    h-index

  2. Diabetes Care

    38 publications · 8.1K citations

    35

    h-index

  3. Current Medical Research and Opinion

    CMRO · 13 publications · 667 citations

    13

    h-index

  4. Diabetic Medicine

    13 publications · 913 citations

    13

    h-index

  5. PubMed

    Repository · 11 publications · 245 citations

    11

    h-index

1–5